1
|
Hassing HA, Engelstoft MS, Sichlau RM, Madsen AN, Rehfeld JF, Pedersen J, Jones RM, Holst JJ, Schwartz TW, Rosenkilde MM, Hansen HS. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor. Biofactors 2016; 42:665-673. [PMID: 27297962 DOI: 10.1002/biof.1303] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Revised: 05/01/2016] [Accepted: 05/18/2016] [Indexed: 12/26/2022]
Abstract
The intestinal G protein-coupled receptor GPR119 is a novel metabolic target involving glucagon-like peptide-1 (GLP-1)-derived insulin-regulated glucose homeostasis. Endogenous and diet-derived lipids, including N-acylethanolamines and 2-monoacylglycerols (2-MAG) activate GPR119. The purpose of this work is to evaluate whether 2-oleoyl glycerol (2-OG) improves glucose tolerance through GPR119, using wild type (WT) and GPR 119 knock out (KO) mice. We here show that GPR119 is essential for 2-OG-mediated release of GLP-1 and CCK from GLUTag cells, since a GPR119 specific antagonist completely abolished the hormone release. Similarly, in isolated primary colonic crypt cultures from WT mice, GPR119 was required for 2-OG-stimulated GLP-1 release while there was no response in crypts from KO mice. In vivo, gavage with 2-oleyl glyceryl ether ((2-OG ether), a stable 2-OG analog with a potency of 5.3 µM for GPR119 with respect to cAMP formation as compared to 2.3 µM for 2-OG), significantly (P < 0.05) improved glucose clearance in WT littermates, but not in GPR119 KO mice. Finally, deletion of GPR119 in mice resulted in lower glucagon levels, whereas the levels of insulin and GIP were unchanged. In the present study we show that 2-OG stimulates GLP-1 secretion through GPR119 activation in vitro, and that fat-derived 2-MAGs are potent candidates for mediating fat-induced GLP-1 release through GPR119 in vivo. © 2016 BioFactors, 42(6):665-673, 2016.
Collapse
Affiliation(s)
- H A Hassing
- Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - M S Engelstoft
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Metabolic Receptology and Enteroendocrinology, Novo Nordisk Foundation Center for Metabolic Research, University of Copenhagen, Blegdamsvej 3, Copenhagen, 2200, Denmark
| | - R M Sichlau
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Metabolic Receptology and Enteroendocrinology, Novo Nordisk Foundation Center for Metabolic Research, University of Copenhagen, Blegdamsvej 3, Copenhagen, 2200, Denmark
| | - A N Madsen
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - J F Rehfeld
- Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej, Copenhagen, Denmark
| | - J Pedersen
- Department of Biomedical Science, Endocrinology Research Section, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - R M Jones
- Arena Pharmaceutical Inc, San Diego, CA, 92121, USA
| | - J J Holst
- Department of Biomedical Science, Endocrinology Research Section, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Translational Physiology, Novo Nordisk Foundation Center for Metabolic Research, Panum Institute, Blegdamsvej 3, Copenhagen, Denmark
| | - T W Schwartz
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
- Section for Metabolic Receptology and Enteroendocrinology, Novo Nordisk Foundation Center for Metabolic Research, University of Copenhagen, Blegdamsvej 3, Copenhagen, 2200, Denmark
| | - M M Rosenkilde
- Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark
| | - H S Hansen
- Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark
| |
Collapse
|